Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote & History ...

Find the latest Denali Therapeutics Inc. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing.

CouponFollow Extension

5%
OFF

JPMorgan Chase & Co. Purchases 14,324 Shares Of Denali …

3 weeks from now

Jan 16, 2025 · JPMorgan Chase & Co. raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.5% during the third quarter, according to its most recent …

marketbeat.com

$0.00
OFF

Denali Therapeutics (DNLI) Stock Price, News & Analysis

3 weeks from now

3 days ago · In the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company …

marketbeat.com

4%
OFF

Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased By

3 weeks from now

Dec 19, 2024 · Barclays PLC increased its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 101.4% in the 3rd quarter, according to its most recent 13F filing with the …

marketbeat.com

$40.00
OFF

Denali Therapeutics (NASDAQ:DNLI) Price Target Cut To $40.00 By ...

3 weeks from now

18 hours ago · Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last announced its earnings results …

etfdailynews.com

FAQs about Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote & History ... Coupon?

What percentage of Denali Therapeutics stock is owned by insiders?

In the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,576,982.00 in company stock. Only 7.90% of the stock of Denali Therapeutics is held by insiders. 92.92% of the stock of Denali Therapeutics is held by institutions. ...

Is Denali Therapeutics a good stock to buy?

Raymond James reaffirmed a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Finally, Jefferies Financial Group upped their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. ...

Should you buy Denali Therapeutics (dnl343) stock?

According to 13 analysts, the average rating for DNLI stock is "Strong Buy." The 12-month stock price forecast is $38.91, which is an increase of 98.62% from the latest price. Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. ...

How much did Denali Therapeutics (dnli) raise in an IPO?

Denali Therapeutics (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. ...

What is the target price for Denali Therapeutics?

The 33 analysts offering price forecasts for Denali Therapeutics have a median target of 64.18, with a high estimate of 105.00 and a low estimate of 22.00. The median estimate represents a 34.14 difference from the last price of 21.91. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. ...

Who is Denali Therapeutics?

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. ...